DC-CIK疗法联合化疗治疗晚期非小细胞肺癌  

Curative Effect of DC-CIK Therapy Combined with Chemotherapy in the Treatment of Patients with Advanced Non-small Cell Lung Cancer

作　　者：秦亚光[1] 程传耀[1] 王亚秋[1] 卢红[1] 

机构地区：[1]河南大学淮河医院肿瘤科,河南开封475000

出　　处：《肿瘤基础与临床》2015年第6期497-500,共4页journal of basic and clinical oncology

摘　　要：目的研究DC-CIK疗法联合化疗治疗晚期非小细胞肺癌的疗效及安全性。方法 52例晚期非小细胞肺癌患者(DC-CIK组)应用DC-CIK疗法联合化疗治疗,同期52例(对照组)仅给予化疗,比较2组疗效和安全性。结果 DC-CIK组患者的有效率、疾病控制率分别为26.9%、82.7%,显著高于对照组的9.6%、61.5%(P<0.05);DC-CIK组和对照组中位生存期分别为12.5、11.3个月(P<0.05)。DC-CIK组患者的毒副反应明显轻于对照组(P<0.05)。结论在晚期非小细胞肺癌的治疗中,DC-CIK疗法联合相较于单纯化疗更安全、更有效。Objective To evaluate the curative effect and safety of DC-CIK therapy combined with chemotherapy in the treatment of patients with advanced non-small cell lung cancer. Methods Fifty-two patients with advanced non-small cell lung cancer （the DC-CIK group）received the DC-CIK therapy combined with chemotherapy, Another 52 patients with advanced non-small cell lung cancer （the control group）were treated with chemotherapy alone during the same period. The effect and safety were compared between the two groups. Results The response rate and the disease control rate of the DC-CIK group were higher than those of the control group （26.9% vs 9.6% ,82.7% vs 61.5% ,P 〈0.05） ; the middle survival time of the DC-CIK group and the control group were 12.5 and 11.3 months respectively （P 〈 0.05 ）. Compared with the control group, the DC-CIK group had less toxicities （ P 〈 0.05）. Conclusion DC-CIK therapy combined with chemotherapy is safe and effect in the treatment of patients with advanced non-small cell lung cancer.

关 键 词：DC—CIK疗法 晚期非小细胞肺癌 过继免疫细胞治疗 化疗 

分 类 号：R734.2[医药卫生—肿瘤] R730.58[医药卫生—临床医学]